Skip to content
OpenCapital
Get started

Tandem Diabetes Care TNDM Acquired in-process research and development

Acquired in-process research and development at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$71.22M—

Other financials

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%
Free cash flow$4.8M+123%

Valuation

See full
Market cap$1.08B-19.8%
Enterprise value$1.64B-8.5%
P/S1.1×-0.3×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tandem Diabetes Care's acquired in-process research and development?
Tandem Diabetes Care (TNDM) reported acquired in-process research and development of $0 in Q1 2026.
How has Tandem Diabetes Care's acquired in-process research and development changed year-over-year?
Tandem Diabetes Care's acquired in-process research and development decreased by 100.0% year-over-year, from $75.22M to $0.
What is the long-term trend for Tandem Diabetes Care's acquired in-process research and development?
Over 3 years (2022 to 2025), Tandem Diabetes Care's acquired in-process research and development has grown at a 34.3% compound annual growth rate (CAGR), from $31.04M to $75.22M.
What does acquired in-process research and development mean?
This represents the cash outflow for the acquisition of research and development projects that have not yet reached technological feasibility or regulatory approval. It is a critical indicator of a company's commitment to external innovation and long-term pipeline expansion. High levels of this expenditure suggest an aggressive growth strategy through inorganic R&D investment.